These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2475521)

  • 41. Interferon production and tumor cell killing by human lymphocytes stimulated in mixed-lymphocyte culture.
    Peterman GM; Stanton GJ; Altman LC; Klimpel GR
    Cell Immunol; 1984 Apr; 85(1):114-24. PubMed ID: 6201284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-gamma production by human natural killer effectors.
    Terrazzano G; Zanzi D; Palomba C; Carbone E; Grimaldi S; Pisanti S; Fontana S; Zappacosta S; Ruggiero G
    J Leukoc Biol; 2002 Aug; 72(2):305-11. PubMed ID: 12149421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens.
    Dazzi F; D'Andrea E; Biasi G; De Silvestro G; Gaidano G; Schena M; Tison T; Vianello F; Girolami A; Caligaris-Cappio F
    Clin Immunol Immunopathol; 1995 Apr; 75(1):26-32. PubMed ID: 7882591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
    Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
    Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating the mechanism underlying antitumor effect of interleukin 27 on B cells of chronic lymphocytic leukemia patients.
    Manouchehri-Doulabi E; Abbaspour S; Rostami S; Faranoush M; Ghahramanfard F; Pak F; Barati M; Kokhaei P; Momtazi-Borojeni AA
    J Cell Physiol; 2020 Dec; 235(12):9424-9431. PubMed ID: 32383245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.
    Lotz M; Ranheim E; Kipps TJ
    J Exp Med; 1994 Mar; 179(3):999-1004. PubMed ID: 8113691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquisition of suppressive activity and natural killer-like cytotoxicity by human alloproliferative "helper" T cell clones.
    Pawelec G; Schneider EM; Wernet P
    J Immunol; 1986 Jan; 136(2):402-11. PubMed ID: 2934470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens.
    Phillips JH; Le AM; Lanier LL
    J Exp Med; 1984 Apr; 159(4):993-1008. PubMed ID: 6231353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern.
    Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Osterborg A; Rabbani H
    Br J Haematol; 2001 Nov; 115(2):263-71. PubMed ID: 11703320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS).
    Kimby E; Mellstedt H; Nilsson B; Björkholm M; Holm G
    Leukemia; 1989 Jul; 3(7):501-4. PubMed ID: 2471902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specific features of T- and NK-cellular immunity in chronic lymphocytic leukemia.
    Pochtar EV; Lugovskaya SA; Naumova EV; Dmitrieva EA; Kostin AI; Dolgov VV
    Klin Lab Diagn; 2021 Jun; 66(6):345-352. PubMed ID: 34105910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
    Robertson LE; Denny AW; Huh YO; Plunkett W; Keating MJ; Nelson JA
    Cancer Chemother Pharmacol; 1996; 37(5):445-50. PubMed ID: 8599867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
    Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
    Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
    Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
    Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Production of B-cell growth factor interleukin 2 and gamma interferon by peripheral blood lymphocytes from patients with chronic lymphocytic leukemia of B-cell type.
    Rossi JF; Commes T; Grenier J; Jourdan M; Chichehian B; Klein B
    Am J Hematol; 1988 Dec; 29(4):183-8. PubMed ID: 3142255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL).
    Zocchi MR; Poggi A; Heltai S; Villa A; Inverardi L; Vicari A; Sabbadini MG; Ferrarini M
    Clin Exp Immunol; 1990 Oct; 82(1):108-13. PubMed ID: 1976463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
    Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
    Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.